WOUND HEALING BY CONTINUOUS LACTATE DELIVERY

Information

  • Research Project
  • 2023045
  • ApplicationId
    2023045
  • Core Project Number
    R43GM052788
  • Full Project Number
    1R43GM052788-01A2
  • Serial Number
    52788
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/1997 - 28 years ago
  • Project End Date
    3/31/1998 - 27 years ago
  • Program Officer Name
  • Budget Start Date
    6/1/1997 - 28 years ago
  • Budget End Date
    3/31/1998 - 27 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    5/30/1997 - 28 years ago
Organizations

WOUND HEALING BY CONTINUOUS LACTATE DELIVERY

The objective of this application is to develop a system which will provide continuous release of lactate to wounds. These studies will determine if continuous application of lactate, which has been shown to stimulate collagen production by fibroblasts and to stimulate angiogenesis factor production in macrophages, will stimulate accelerated wound healing in vivo. Polylactide microspheres will be made which will release lactate at various rates. The microspheres will be tested in an incisional wound healing model in rats to determine their ability to enhance wound breading strengths. If these polylactide microspheres are effective they would provide an easy, safe, and relatively inexpensive way to treat acute and chronic wounds which would otherwise result in serious complications to the patient. The long term goal would be to develop a product which could be tailored to work in a wide range of wound healing and angiogenic applications. PROPOSED COMMERCIAL APPLICATION The complications associated with problem acute and chronic non-healing wounds in the USA is enormous. Approximately 250,000 patients experience partial or complete fascial disruption of their acute abdominal wounds each year while hundreds of thousands of diabetics and other patients with chronic wounds undergo a constant battle with recurring wounds which often result in eventual loss of limbs. A safe and effective treatment for these wounds would have obvious commercial potential and would result in substantial health care savings for society.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    EMBRO CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    ST. LOUIS PARK
  • Organization State
    MN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    55416
  • Organization District
    UNITED STATES